These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16537732)

  • 21. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear.
    Reed BD
    Arch Fam Med; 1996; 5(10):582-4. PubMed ID: 8930230
    [No Abstract]   [Full Text] [Related]  

  • 23. Cervical screening: management of patients referred for colposcopy with smear abnormalities less severe than dyskaryosis.
    Usman F; Hammond R
    Cytopathology; 1998 Apr; 9(2):100-6. PubMed ID: 9577736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV testing alone is not as safe as cytology and selective HPV testing: AGAINST: There is powerful evidence for primary cervical screening.
    Kitchener H
    BJOG; 2016 Jan; 123(1):68. PubMed ID: 26527427
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening for cervical cancer.
    Ronco G; Meijer CJ; Cuzick J; Giorgi-Rossi P; Peto J; Segnan N; Dillner J
    Ann Intern Med; 2012 Apr; 156(8):604-5; author reply 605-6. PubMed ID: 22508738
    [No Abstract]   [Full Text] [Related]  

  • 26. Screening for cervical cancer.
    CA Cancer J Clin; 2020 Sep; 70(5):347-348. PubMed ID: 33460047
    [No Abstract]   [Full Text] [Related]  

  • 27. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer.
    Lytwyn A; Elit L; Sellors JW
    N Engl J Med; 2008 Feb; 358(6):641; author reply 643. PubMed ID: 18256402
    [No Abstract]   [Full Text] [Related]  

  • 28. HPV16 and HPV18 genotyping in cervical cancer screening.
    Ronco G; Franceschi S; Segnan N
    Lancet Oncol; 2011 Sep; 12(9):831-2. PubMed ID: 21865085
    [No Abstract]   [Full Text] [Related]  

  • 29. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
    Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
    Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Proposal for the modernization of cervical screening procedure in Hungary].
    Koiss R; Boncz I; Hernádi Z; Szentirmay Z
    Orv Hetil; 2017 Dec; 158(52):2062-2067. PubMed ID: 29285941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cervical screening in adolescents--at least do no harm.
    Szarewski A; Sasieni P
    Lancet; 2004 Nov 6-12; 364(9446):1642-4. PubMed ID: 15530605
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of transitioning from cytology to human papillomavirus-based cervical cancer screening.
    Hammer A; Gravitt P
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):371-372. PubMed ID: 33739440
    [No Abstract]   [Full Text] [Related]  

  • 35. Considerations to inform minimum slide numbers to maintain cytology triage screening competencies.
    Nuttall D
    Cytopathology; 2022 Nov; 33(6):746-748. PubMed ID: 35864602
    [No Abstract]   [Full Text] [Related]  

  • 36. Global challenges of cervical cancer prevention.
    Monsonego J
    Clin Exp Obstet Gynecol; 2001; 28(1):5-13. PubMed ID: 11332590
    [No Abstract]   [Full Text] [Related]  

  • 37. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
    Saslow D; Solomon D; Lawson HW; Killackey M; Kulasingam SL; Cain J; Garcia FA; Moriarty AT; Waxman AG; Wilbur DC; Wentzensen N; Downs LS; Spitzer M; Moscicki AB; Franco EL; Stoler MH; Schiffman M; Castle PE; Myers ER; ; ;
    Am J Clin Pathol; 2012 Apr; 137(4):516-42. PubMed ID: 22431528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal pap smears in adolescents.
    Bacon J; Francoeur D; Goldfarb AF; Breech LL
    J Pediatr Adolesc Gynecol; 2003 Jun; 16(3):157-66. PubMed ID: 12804941
    [No Abstract]   [Full Text] [Related]  

  • 40. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme.
    Luyten A; Buttmann-Schweiger N; Luyten K; Mauritz C; Reinecke-Lüthge A; Pietralla M; Meijer CJ; Petry KU
    Int J Cancer; 2014 Sep; 135(6):1408-16. PubMed ID: 24519782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.